Mercados españoles cerrados

Invitae Corporation (NVTA)

NYSE - NYSE Precio demorado. Divisa en USD
Añadir a la lista de favoritos
40,13+0,33 (+0,83%)
Al cierre: 4:00PM EST
Inicia sesión para publicar un mensaje.
  • B
    Pacific Biosciences of California, Inc.
    2021 year of the biotechs, $PACB, $NVTA, $NTLA, all going to double and more.
  • O
    I like Invitae because it seems to be the market-leader in making genetic-diagnostic testing the standard of care, especially cost wise. I see only opportunity for more bespoke testing, upsell solutions to existing customer base, and a huge total addressable market, plus first-mover advantage with providers.

    What I’m failing to understand is why $NVTA is consistently compared to $BNGO. The latter seems less consumer-facing, more B2B and more hardware focused with visualization software. Am I correct in that NVTA is more likely to be a client of BNGO than the other way around?

    NVTA’s model appears to be a lot more scalable. They seem less competitors and more complimentary pieces within the same puzzle.

    For those in the medical field, what exactly makes BNGO’s technology superior? My layperson view is that NVTA does gene-sequencing at a high-level for efficiency, while BNGO does gene-mapping at a MUCH closer and granular view - albeit higher cost? BNGO claims to be better than Next-Gen sequencing but the key question is whether their product is more than the market requires, whereas NVTA is a mass-solution, more accessible to people and providers.

    I’m currently long $NVTA and have yet to buy $BNGO. Curious if anyone owns both, and if so, what your distinction is between the two. Thanks!
  • E
    CRISPR Therapeutics AG
    $CRSP and the other genomic plays ($EDIT $NTLA $NVTA $PACB) are the kind of stocks that you shouldn't be buying based purely on valuation. you either believe in the potential or you dont.
    for those of us that believe, I think we will rewarded 10x over. IMO
  • S
    Silent H
    $NVTA conversation
    How much $NVTA does ARK own? Didn't they pick up more recently?
  • W
    William Wallace
    $EXAS conversation
    $VGAC now 23 and me

  • S
    Short Master
    $BNGO conversation
    All Genomics Stocks

  • J
    Joe Da Man
    $PLTR conversation
    That's the stock market for ya. Like a movie. $NVTA was up 9% the whole day and end up down 4%. This one was down and end up green.
  • J
    Wall st loading as u panic $edit $ntla $nvta
  • U
    $CERS conversation
    Price action is strange here. Ark ups stake 30% to 21 million shares of $cers. Given how they've done with $nvta and many others, this should have moved the price to a 52 week high... easily. Especially in this speculative market and with near term catalysts. Finding it bizarre....
  • L
    $NVTA conversation
    Three weeks ago I noted that the projected revenue for Q1 was only $24M. That figure is gone now, and has been replaced by $27.09M. The highest estimate is $29.67M and that would take about 62,000 tests.

    That's nice, but my hope is that $NVTA turns in 63,000 tests and reports $30.2M for Q1.
  • J
    Hey cathy wood genomics bubble muppets check out $arct we r coming for u $ntla $edit $crspr $nvta
  • N
    $NVTA conversation
    It’s easily the most overlooked megatrend I’ve ever written about.
    It’s easily the most overlooked megatrend I’ve ever written about.
  • J
    Market accumulating all day on fake sell off $ntla $nvta
  • J
    Markets going up 5% tomorrow:


  • J
    $NVTA conversation
    If you want to look at the doji chart pattern for $NVTA we have a huge engulfing bull candlestick, combined with a bounce off oversold RSI levels. Classic reversal pattern. Shorts could get crushed if they don't close out their positions.
  • K
    Set it and FORGET IT. My biggest holding yet the one i stress the least without question. Heading for 40-50 this calendar year is IMMINENT. Let’s gooooo #NVTA
  • K
    $SRPT conversation
    More kids more patients:
    $SRPT and $NVTA Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy
  • R
    $PSTH conversation
    Bloomberg feed:

    You think Snowflake was big? Well, let me tell you a thing or two. Bill Ackman's ego is even bigger, and with the largest SPAC in history he is going to have the most blockbuster listing. It's going to be so huge, even Buffett's chair is going to wobble when he sees this. He's got a war chest of 4 billion with additional capital he can allocate up to 7 billion. No fees. The only performance he get's is the appreciation of the stock price.

    Airbnb thinks it's cute telling everyone they are going to go the IPO route, but let's be real tea, they cannot wait that long for a cash infusion and don't want to leave money on the table or risk falling below their IPO price with a valuation by the public uncertain. That was a cute trick to try fool Ackman they have other options, but they really don't. No more growth equity money is going into that.

    Ackman has stated many times he wants a deal done this year and that now is the time. He already made arguably the best YOLO in history, turning 2.7m into 2.7b in about 10 days. He's on fire and is going to do it with PSTH.

    I'm basically all-in.


    $PSTH 3/19/21 20c & 25c

    Target Price: $40+

    Note my previous YOLO: $NVTA is ITM.
  • P
    $NNDM conversation
    My first reaction this morning was "what the f...", but I'm still thinking what happened beginning of April on $NVTA when they announced a direct offering of shares for 10$. The stock plunged 25% at the opening, Unfortunately I didn't buy, the stock started to recuperate and when it got back to my entry price I sold. That has been my biggest mistake of the year. We can all see where it is now. Will the same happen here? Of course I'm not sure but they're good possibilities it will. ARK was, then also, in $NVTA.
  • v
    Invitae Corporation
    Invitae Reports $216.8 Million in Annual Revenue Driven by More Than 482,000 Samples in 2019 $NVTA